AHA 2023

At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic Pressure and plasma BNP, and increased Cardiac Output and natriuresis, without affecting Systolic Blood Pressure. The CRF2 receptor agonist, COR-1167, is a potential new treatment for HF.